Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 10/20 | 0.56 |
| ▸ | OPRM1 | P35372 | 12/20 | 0.56 |
| ▸ | OPRK1 | P41145 | 10/20 | 0.56 |
| ▸ | MRGPRX2 | Q96LB1 | 2/20 | 0.51 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.50 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.50 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Myrophine SCHEMBL29851007 | 1.00 | OPRD1 (0.56) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL3477477 | 0.89 | OPRM1 (0.71) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL7775794 | 0.89 | OPRM1 (0.71) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL7770909 | 0.89 | OPRM1 (0.71) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL3477727 | 0.86 | OPRM1 (0.73) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL29610430 | 0.85 | OPRM1 (0.77) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL22959877 | 0.85 | OPRM1 (0.77) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL3477203 | 0.84 | OPRM1 (0.70) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 | |
| SCHEMBL8208039 | 0.83 | OPRM1 (0.62) | OPRD1OPRM1OPRK1 | |
| SCHEMBL19463540 | 0.83 | OPRD1 (0.72) | OPRD1OPRM1OPRK1MRGPRX2ADRB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Appears in 6219 patents — a generic fragment claimed broadly, so it's down-weighted as IP noise. Top by claim status then date:
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4724049-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | Catalent Ontario Limited (CA) | 2026-04-15 | — | — | EP | claimed |
| US-20250319074-A1 | TREATMENT AND MANAGEMENT OF AUGMENTATION IN RESTLESS LEGS SYNDROME | UNIV EAST CAROLINA (US) | 2025-10-16 | — | — | US | claimed |
| US-12383743-B2 | Treatment of addiction and dependency | TACA JR ARTURO C (US) | 2025-08-12 | — | — | US | claimed |
| US-20250228771-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-07-17 | — | — | US | claimed |
| EP-4581017-A1 | NEW N-HETEROARYLBENZAMIDES DERIVATIVES AS FLT3 INHIBITORS | Biodol Therapeutics (FR) | 2025-07-09 | — | — | EP | claimed |
| EP-4565202-A1 | ALKALINE INTRAORAL PRODUCTS | EMPLICURE AB (publ) (SE) | 2025-06-11 | — | — | EP | claimed |
| WO-2024254056-A1 | MODIFIED RELEASE FILL COMPOSITIONS FOR DOSAGE FORMS AND METHODS OF PREPARATION AND USE THEREOF | CATALENT ONTARIO LIMITED (CA) | 2024-12-12 | — | — | WO | claimed |
| US-12133922-B2 | Abuse resistant capsule | R.P. SCHERER TECHNOLOGIES, LLC (US) | 2024-11-05 | — | — | US | claimed |
| US-20240288374-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation | 2024-08-29 | — | — | US | claimed |
| WO-2024172892-A1 | PLASMONIC NANOPARTICLE PLATFORM FOR ANALYTE DETECTION | Zymeron Corporation (US) | 2024-08-22 | — | — | WO | claimed |
| US-5958452-A | SUSTAINED RELEASE FORMULATION COMPRISING EXTRUDED BLEND OF DRUG, HYDROPHOBIC MATERIAL, HYDROPHOBIC FUSIBLE CARRIER DIVIDED INTO UNIT DOSE | EURO-CELTIQUE, S.A. (LU) | 1999-09-28 | — | — | US | claimed |
| WO-1999013799-A1 | SYNERGISTIC ANALGESIC COMBINATION OF OPIOID ANALGESIC AND CYCLOOXYGENASE-2 INHIBITOR | EURO-CELTIQUE, S.A. (LU) | 1999-03-25 | — | — | WO | claimed |
| EP-0785775-A4 | MELT-EXTRUDED ORALLY ADMINISTRABLE OPIOID FORMULATIONS | EURO CELTIQUE SA (LU) | 1998-08-19 | — | — | EP | claimed |
| EP-0785775-A1 | MELT-EXTRUDED ORALLY ADMINISTRABLE OPIOID FORMULATIONS | Euroceltique S.A. (LU) | 1997-07-30 | — | — | EP | claimed |
| EP-0731694-A4 | — | — | 1996-10-02 | — | — | EP | claimed |
| EP-0731694-A1 | OPIOID FORMULATIONS FOR TREATING PAIN | Euroceltique S.A. (LU) | 1996-09-18 | — | — | EP | claimed |
| CN-1130352-A | Method for relieving pain by orally administering 24-hour sustained-release opioid dosage form capable of rapidly increasing initial blood concentration of patient | EURO CELTIQUE SA (LU) | 1996-09-04 | — | — | CN | claimed |
| WO-1996014058-A1 | MELT-EXTRUDED ORALLY ADMINISTRABLE OPIOID FORMULATIONS | EURO-CELTIQUE, S.A. (LU) | 1996-05-17 | — | — | WO | claimed |
| WO-1995014460-A1 | OPIOID FORMULATIONS FOR TREATING PAIN | EURO-CELTIQUE S.A. (LU) | 1995-06-01 | — | — | WO | claimed |
| EP-0647448-A1 | Orally administrable opioid formulations having extended duration of effect | Euroceltique S.A. (LU) | 1995-04-12 | — | — | EP | claimed |